ExoLab Italy Secures €5 Million in Series A
Deal News | Feb 26, 2025 | CDP Venture Capital
ExoLab Italy, an innovative startup specializing in products derived from plant-based exosomes, has successfully closed a Series A funding round totaling €5 million. The investment round, led by CDP Venture Capital, includes contributions from a consortium of investors. This capital injection aims to support ExoLab's ambitious plans for international expansion. ExoLab's focus on leveraging plant-derived exosomes positions it uniquely within the biotech industry, providing promising applications in various sectors. The successful funding round marks a significant milestone for ExoLab as it seeks to extend its reach beyond Italy and solidify its presence in the global market.
Sectors
- Biotechnology
- Venture Capital
Geography
- Italy – ExoLab Italy is headquartered in Italy, and the funding round involves Italian investors.
- International – The investment is targeted towards supporting ExoLab's international expansion efforts.
Industry
- Biotechnology – ExoLab Italy operates in the biotechnology industry by creating products based on plant-derived exosomes.
- Venture Capital – The involvement of CDP Venture Capital in funding highlights the participation of the venture capital industry.
Financials
- €5 Million – The total amount raised by ExoLab Italy in its Series A funding round.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| ExoLab Italy | Target company | Company | A startup focused on producing plant-derived exosomes. |
| CDP Venture Capital | Investor | Company | A venture capital firm that led the Series A funding round for ExoLab Italy. |
| Group of Investors | Investors | Company | A consortium involved in supporting ExoLab Italy's funding round. |